SKINVISIBLE Faces Substantial Doubt on Going Concern Amidst Deepening Losses, Precarious Liquidity, and Material Weakness in Controls

summarizeSummary

SKINVISIBLE's annual report reveals critical financial instability with a going concern warning, deepening losses, minimal cash, and a material weakness in internal controls, despite positive clinical progress from its licensing partner.

check_boxKey Events

• Going Concern Warning Issued

  The company's financial statements include a going concern warning due to recurring losses, negative cash flows, and an accumulated deficit of $41,010,176, raising substantial doubt about its ability to continue operations.

• Significant Net Loss Reported

  SKINVISIBLE reported a net loss of $1,064,034 for the year ended December 31, 2025, a substantial increase from $565,654 in 2024, on minimal revenue of $20,000.

• Precarious Liquidity Position

  As of December 31, 2025, the company had only $2,620 in cash, a working capital deficit of $4,990,414, and total liabilities of $10,390,348, indicating severe financial strain.

• Material Weakness in Internal Controls

  Management identified a material weakness in internal controls over financial reporting, specifically due to inadequate segregation of duties and an ineffective risk assessment process, posing significant financial reporting risks.

auto_awesomeAnalysis

This annual report highlights severe financial distress for SKINVISIBLE, raising substantial doubt about its ability to continue as a going concern. The company reported a significant net loss of over $1 million for 2025, contributing to cumulative losses exceeding $41 million, against a market capitalization of only $1.28 million. Its cash position is critically low at $2,620, with a working capital deficit of nearly $5 million and total liabilities over $10 million. Furthermore, management identified a material weakness in internal controls over financial reporting, indicating significant operational and financial reporting risks. While the company's licensing partner, Quoin Pharmaceuticals, has made positive progress in clinical trials for Netherton Syndrome (including FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations), and SKINVISIBLE has filed new patent applications for obesity and glucose-controlling agents, these future-oriented developments do not address the immediate and severe liquidity crisis. The company's plan to seek additional debt and/or equity financing is crucial for survival, but success is uncertain, and any equity raise would be highly dilutive given the over 1500% potential dilution from existing convertible instruments.